BrainStorm Cuts 30% of Staff to Refocus on ALS Cell Therapy’s New Phase 3 Trial
A month after an FDA advisory committee voted against recommending approval of BrainStorm Cell Therapeutics’ stem cell therapy for ALS, the company is preparing to try again with a new Phase 3 study. To help pay for it, the biotech is restructuring and laying off 30% of its staff.